SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFC14A - Definitive proxy statement, contested solicitations:
SEC Accession No. 0001437749-22-028432
Filing Date
2022-12-05
Accepted
2022-12-05 17:12:17
Documents
6

Document Format Files

Seq Description Document Type Size
1 FORM DEFC14A dffn20221202_defc14a.htm DEFC14A 544724
2 a01.jpg GRAPHIC 817666
3 a02.jpg GRAPHIC 854805
4 dffn20221117_prec14aimg001.jpg GRAPHIC 7826
5 dffn20221117_prec14aimg002.jpg GRAPHIC 7339
6 dffn20221117_prec14aimg003.jpg GRAPHIC 7339
  Complete submission text file 0001437749-22-028432.txt   2873155
Mailing Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902
Business Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filed by) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFC14A
SIC: 2834 Pharmaceutical Preparations

Mailing Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902
Business Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Subject) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFC14A | Act: 34 | File No.: 001-37942 | Film No.: 221445815
SIC: 2834 Pharmaceutical Preparations